ASPIRE - A Study to Prevent Infection with a Ring for Extended Use – is a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral dapivirine that was launched August 2012 and will enroll about 3,476 women at several sites in Africa. The dapivirine vaginal ring was developed by the International Partnership for Microbicides.
See
07/24/2012
Sister Studies: ASPIRE and The Ring Study Fact Sheet
See also
